217 related articles for article (PubMed ID: 30233772)
1. A Review of Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Breast Cancer.
Karadurmus N; Sahin U; Bahadir Basgoz B; Arpaci F; Demirer T
Int J Hematol Oncol Stem Cell Res; 2018 Apr; 12(2):111-116. PubMed ID: 30233772
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer.
Bishop MR; Fowler DH; Marchigiani D; Castro K; Kasten-Sportes C; Steinberg SM; Gea-Banacloche JC; Dean R; Chow CK; Carter C; Read EJ; Leitman S; Gress R
J Clin Oncol; 2004 Oct; 22(19):3886-92. PubMed ID: 15314059
[TBL] [Abstract][Full Text] [Related]
3. Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma.
Maloney DG
Leuk Lymphoma; 2003; 44 Suppl 3():S99-105. PubMed ID: 15202532
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer.
Karadurmus N; Sahin U; Basgoz BB; Arpaci F; Demirer T
World J Transplant; 2016 Dec; 6(4):675-681. PubMed ID: 28058217
[TBL] [Abstract][Full Text] [Related]
7. Graft-versus-cancereffect and innovative approaches in thetreatment of refractory solid tumors.
Şahin U; Demirer T
Turk J Med Sci; 2020 Nov; 50(SI-2):1697-1706. PubMed ID: 32178508
[TBL] [Abstract][Full Text] [Related]
8. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
9. Graft-Versus-Solid-Tumor Effect: From Hematopoietic Stem Cell Transplantation to Adoptive Cell Therapies.
Barisic S; Childs RW
Stem Cells; 2022 Jun; 40(6):556-563. PubMed ID: 35325242
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
Bishop MR
Clin Breast Cancer; 2003 Apr; 4(1):39-45. PubMed ID: 12744757
[TBL] [Abstract][Full Text] [Related]
11. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
12. Nonmyeloablative transplantation for solid tumors: a new frontier for allogeneic immunotherapy.
Espinoza-Delgado I; Childs RW
Expert Rev Anticancer Ther; 2004 Oct; 4(5):865-75. PubMed ID: 15485320
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.
Or R; Ackerstein A; Nagler A; Kapelushnik J; Naparstek E; Samuel S; Amar A; Bruatbar C; Slavin S
Cytokines Cell Mol Ther; 1998 Mar; 4(1):1-6. PubMed ID: 9557210
[TBL] [Abstract][Full Text] [Related]
15. NKG2D expression by CD8+ T cells contributes to GVHD and GVT effects in a murine model of allogeneic HSCT.
Karimi MA; Bryson JL; Richman LP; Fesnak AD; Leichner TM; Satake A; Vonderheide RH; Raulet DH; Reshef R; Kambayashi T
Blood; 2015 Jun; 125(23):3655-63. PubMed ID: 25788701
[TBL] [Abstract][Full Text] [Related]
16. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.
Krishnan A; Pasquini MC; Logan B; Stadtmauer EA; Vesole DH; Alyea E; Antin JH; Comenzo R; Goodman S; Hari P; Laport G; Qazilbash MH; Rowley S; Sahebi F; Somlo G; Vogl DT; Weisdorf D; Ewell M; Wu J; Geller NL; Horowitz MM; Giralt S; Maloney DG;
Lancet Oncol; 2011 Dec; 12(13):1195-203. PubMed ID: 21962393
[TBL] [Abstract][Full Text] [Related]
17. [Hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia].
Liu QF; Sun J; Zhang Y; Liu XL; Xu D; Xu B; Feng R; Meng FY; Zhou SY
Ai Zheng; 2004 Apr; 23(4):426-9. PubMed ID: 15087032
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors.
Demirer T; Barkholt L; Blaise D; Pedrazzoli P; Aglietta M; Carella AM; Bay JO; Arpaci F; Rosti G; Gurman G; Niederwieser D; Bregni M;
Nat Clin Pract Oncol; 2008 May; 5(5):256-67. PubMed ID: 18398414
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation for metastatic breast cancer.
Bishop MR
Haematologica; 2004 May; 89(5):599-605. PubMed ID: 15136224
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-Derived Suppressor Cells in the Context of Allogeneic Hematopoietic Stem Cell Transplantation.
D'Aveni M; Notarantonio AB; Bertrand A; Boulangé L; Pochon C; Rubio MT
Front Immunol; 2020; 11():989. PubMed ID: 32528476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
